CIK 0001211583 · Non-accelerated filer<br>Smaller reporting company
FENNEC PHARMACEUTICALS INC.
Sign in to watch- Ticker
- FENC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (919) 636-4530
- Business address
- PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
- Former names
- ADHEREX TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,310,718
- in 4 filings, $1.2M under 10b5-1 plans
Net −$1,310,718. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,042 | 130,507 | ||
| 2025-01-06 | Raykov Rosty Director | Sale 10b5-1 | −2,431 | $6.08 | $15K | 91,432 |
| 2025-01-06 | Raykov Rosty Director | Sale 10b5-1 | −7,569 | $6.08 | $46K | 83,863 |
| 2024-12-31 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,042 | 129,465 | ||
| 2024-12-31 | Raykov Rosty Director | Grant or award | +2,431 | 93,863 | ||
| 2024-12-20 | Raykov Rosty Director | Option exercise | +25,000 | $2.69 | $67K | 91,432 |
| 2024-12-20 | Raykov Rosty Director | Option exercise · Stock Options | −25,000 | $2.69 | $67K | 1,675,000 |
| 2024-12-05 | Raykov Rosty Director | Sale 10b5-1 | −796 | $6.04 | $5K | 66,432 |
| 2024-12-03 | Raykov Rosty Director | Sale 10b5-1 | −1,635 | $6.13 | $10K | 67,228 |
| 2024-12-02 | Raykov Rosty Director | Grant or award 10b5-1 | +2,431 | 68,863 | ||
| 2024-12-02 | Andrade Robert CHIEF FINANCIAL OFFICER | Grant or award | +1,042 | 128,423 | ||
| 2024-12-02 | RALLIS CHRIS A Director | Option exercise 10b5-1 | +10,000 | $2.69 | $27K | 58,623 |
| 2024-12-02 | RALLIS CHRIS A Director | Sale 10b5-1 | −6,409 | $6.14 | $39K | 52,214 |
| 2024-12-02 | RALLIS CHRIS A Director | Option exercise · Common Shares 10b5-1 | −10,000 | $2.69 | $27K | 184,698 |
| 2024-11-18 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise | +15,816 | $2.45 | $39K | 127,381 |
| 2024-11-18 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise · Stock Options | −15,816 | $2.45 | $39K | 689,184 |
| 2024-11-13 | Cioffi Christiana Marie Chief Strategy Officer | Grant or award · Stock Options | +150,000 | $4.23 | $635K | 150,000 |
| 2024-11-13 | Evans Terry L Chief Commercial Officer | Grant or award · Stock Options | +150,000 | $4.23 | $635K | 150,000 |
| 2024-11-13 | Sayad Pierre Sargis Chief Medical Officer | Grant or award · Stock Options | +150,000 | $4.23 | $635K | 150,000 |
| 2024-11-04 | Raykov Rosty Director | Sale 10b5-1 | −2,431 | $4.31 | $10K | 66,432 |
Page 11 of 17 · 340 trades